Features | Partner Sites | Information | LinkXpress
Sign In
Agfa Healthcare
Schiller
ElsMed

Hepatocellular Carcinoma Screening Linked with Curative Treatment and Longer Survival in Cirrhosis Patients

By Medimaging International staff writers
Posted on 24 Apr 2014
Image: Very high magnification micrograph of fibrolamellar hepatocellular carcinoma showing the characteristic laminated fibrosis between the tumor cells with a low N/C ratio. H&E stain (Photo courtesy of Wikimedia Commons).
Image: Very high magnification micrograph of fibrolamellar hepatocellular carcinoma showing the characteristic laminated fibrosis between the tumor cells with a low N/C ratio. H&E stain (Photo courtesy of Wikimedia Commons).
Investigators discovered that patients with cirrhosis who underwent surveillance (using liver ultrasound with or without measurement of serum alpha fetoprotein) for hepatocellular carcinoma (HCC) had cancers detected at an earlier stage, were more likely to receive curative instead of palliative treatment, and had longer survival.

In a systematic review and meta-analysis of 47 studies with 15,158 patients, Dr. Amit Singal, from the University of Texas Southwestern Medical Center (Dallas, USA) and colleagues reported that the pooled thee-year survival rate across all the studies was 50.8% among the 4,735 patients who underwent HCC surveillance, compared to 27.9% among the 6,115 patients without earlier surveillance (p < 0.001).

The finding of longer survival persisted after the authors limited their review to studies that took into account lead time bias. Lead time bias, as it applies to this study, is the time between when a disease would normally be diagnosed without screening and when the disease is diagnosed with screening. Detecting disease earlier through screening can at times seen be to increase survival when instead it only prolongs the time the person has the diagnosis. However, in this case, studies that accounted for lead time bias statistically still found that screening increased survival. Among the six studies that adjusted for lead time bias, those who underwent HCC surveillance had three-year survival rates of 39.7%, vs. 29.1% among those who did not (p < 0.001).

The authors noted that while screening for HCC in patients with Hepatitis B virus (HBV) infection is supported by a large randomized trial, no such randomized trials exist for patients with cirrhosis. Therefore the authors systematically reviewed published research that evaluated whether screening was associated with improved patient outcomes. While guidelines of the American Association for the Study of Liver Diseases and European Association for the Study of the Liver recommend monitoring with ultrasound every six months in high-risk patients (which includes those with chronic HBV infection and/or cirrhosis), the authors noted that studies have shown that surveillance in the United States is performed in less than 20% of these patients nationally, with lower rates among primary care physicians than gastroenterologists/hepatologists (physicians who specialize in caring for patients with liver disease).

A drawback of the study is that the studies were quite heterogeneous, suggesting benefits of surveillance may not be uniform among all patients, and studies did not include functional status, an important factor in determining appropriate treatment.

The authors concluded that, “the preponderance of data that consistently demonstrate benefits should provide sufficient rationale to recommend HCC surveillance, even in the absence of a randomized controlled trial among patients with cirrhosis.”

Related Links:

University of Texas Southwestern Medical Center



Channels

Radiography

view channel
Image: Agfa HealthCare’s DX-D Mobile Retrofit solution will allow hospitals an easy and affordable way to upgrade existing GE Healthcare’s AMX 4 and 4 plus mobile X-ray systems to direct radiography (DR) (Photo courtesy of Agfa Healthcare).

Retrofit Enables Cost-Effective Upgrade of Existing Mobile X-Ray Systems to Direct Radiography

A mobile retrofit system has been designed to be mounted on mobile X-ray systems to create an easy way for hospitals to go digital without having to replace existing mobile X-ray units. A direct radiography... Read more

MRI

view channel
Image: The ischemic penumbra is visible in some patients up to 24 hour after stroke by MRI scanning. Perfusion-weighted imaging can be used to show areas of ischemia and can be compared with the ischemic core, visible by diffusion-weighted imaging (Photo courtesy of sharinginginhealth dot ca, an open access training in healthcare resource).

Diffusion-Weighted MRI Becoming Major Tool to Diagnose Patients with Transient Ischemic Attacks

With the development of brain imaging, including cranial computed tomography (CCT), and particularly diffusion-weighted imaging-magnetic resonance imaging (DWI-MRI), the diagnosis of transient ischemic... Read more

Nuclear medicine

view channel

PET/CT Using FDG-Labeled Leukocytes Detects Infection in Acute Pancreatitis Patients

A study out of India that identifies infection in patients with pancreatic fluid collections may rapidly and effectively rule out active infection in the body. This treatment may help in making nuclear medicine imaging a mainstay in clinical management practices. Acute pancreatitis (AP) is an abrupt inflammation of the pancreas.... Read more

General/Advanced Imaging

view channel

Diagnostic Imaging Tests Ordered by General Practitioners in Australia Nearly Double in 10 Years

A 45% increase in diagnostic imaging tests ordered by Australian general practitioners (GPs) is being fueled by increasing GP visits, an escalating number of problems managed at doctor visits, and a higher probability that GPs order imaging tests for these problems, according to a new study. Based on a long-term national... Read more

Imaging IT

view channel
Image: An X-ray using the ClearRead bone suppression software technology (Photo courtesy of Riverain Technologies).

Bone Suppression Software Used to Optimize Diagnostic Capability of X-Ray Systems

Clinicians are gathering important information from the most routine imaging exam, the chest X-ray, by using advanced software that enhances X-ray images captured by the equipment they already have or... Read more

Industry News

view channel

Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.